BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ultomiris (Ravulizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ultomiris (Ravulizumab)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06449001-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Paroxysmal Nocturnal Hemogl
 obinuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or
  Eculizumab in Pediatric Participants With PNH Who Have Clinically Signifi
 cant Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308574-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Ultomiris (Ravulizumab): Phase 4 readout est. (NCT07308574)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 4.\nStudy: Post-Marketing Clini
 cal Study of Ravulizumab in Participants With Clinical aHUS\nEstimated pri
 mary completion: 25 June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ravulizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07308574
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596784-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07596784)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Myasthenia Gravis.\nStudy: 
 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Gen
 eralized Myasthenia Gravis (gMG)\nEstimated primary completion: 24 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0759678
 4
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221838-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Ultomiris (Ravulizumab): Phase 4 readout est. (NCT07221838)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 4\, Myasthenia Gravis.\nStudy: 
 A Study to Investigate OCS Tapering in Adult Participants With Generalized
  Myasthenia Gravis Treated With Ravulizumab\nEstimated primary completion:
  27 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ravu
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07221838
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830798-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06830798)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3.\nStudy: Double-blind\, Rando
 mized\, Placebo-controlled\, Multicenter Study to Evaluate the Efficacy an
 d Safety of Ravulizumab Administered Intravenously in Adult Participants a
 t High Risk of Delayed Graft Function After Kidney Transplantation\nEstima
 ted primary completion: 30 November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06830798
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557420-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07557420)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3.\nStudy: Efficacy\, Safety\, 
 Pharmacokinetics\, Pharmacodynamics\, and Immunogenicity Study of Ravulizu
 mab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)\
 nEstimated primary completion: 19 September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07557420
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024563-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281129
DTEND;VALUE=DATE:20281130
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07024563)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, IgA Nephropathy.\nStudy: St
 udy of Ravulizumab in Pediatric Participants With Primary IgAN\nEstimated 
 primary completion: 29 November 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07024563
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333652-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ultomiris (Ravulizumab): Phase 2 readout est. (NCT06333652)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 2.\nStudy: Ravulizumab in Pregn
 ancies Complicated by Severe Hypertensive Disorders\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ravulizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06333652
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010302-885@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Ultomiris (Ravulizumab): Phase 4 readout est. (NCT07010302)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 4.\nStudy: Rituximab Versus Rav
 ulizumab\, Inebilizumab\, Satralizumab\, and Eculizumab in NMOSD\nEstimate
 d primary completion: January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07010302
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
